InsiderClue
Insiders · Profile

RA CAPITAL MANAGEMENT, L.P.

Director at Sionna Therapeutics · Director at Septerna · Director at Artiva Biotherapeutics · and 38 more. Filing since 15 Apr 2008. CIK 0001346824

SION Sionna Therapeutics, Inc. Director · 9 trades SEPN Septerna, Inc. Director · 2 trades ARTV Artiva Biotherapeutics, Inc. Director · 20 trades PBLS Parabilis Medicines, Inc. Director · 4 trades VOR Vor Biopharma Inc. 10% owner · 24 trades HOWL Werewolf Therapeutics, Inc. 10% owner · 18 trades COAG Hemab Therapeutics Holdings, Inc. 10% owner · 11 trades WVE Wave Life Sciences, Inc. Director · 10 trades MLYS Mineralys Therapeutics, Inc. Director · 5 trades BCAX Bicara Therapeutics Inc. Director · 2 trades ACET Adicet Bio, Inc. 10% owner · 3 trades SGP SpyGlass Pharma, Inc. Director · 1 trade CLYM Climb Bio, Inc. Director · 5 trades FULC Fulcrum Therapeutics, Inc. 10% owner · 8 trades EVMN Evommune, Inc. Director · 1 trade PEPG PepGen Inc. Director · 3 trades TYRA Tyra Biosciences, Inc. Director · 8 trades JANX Janux Therapeutics, Inc. Director · 6 trades ANTX AN2 Therapeutics, Inc. 10% owner · 10 trades JBIO Jade Biosciences, Inc. Director · 2 trades BOLD Boundless Bio, Inc. 10% owner · 1 trade NKTX Nkarta, Inc. Director · 3 trades SPRY ARS Pharmaceuticals, Inc. Director · 5 trades LENZ LENZ Therapeutics, Inc. Director · 2 trades SLDB Solid Biosciences Inc. Director · 2 trades ABOS Acumen Pharmaceuticals, Inc. Director · 2 trades BDTX Black Diamond Therapeutics, Inc. Director · 1 trade ELVN Enliven Therapeutics, Inc. 10% owner · 10 trades ACRV Acrivon Therapeutics, Inc. Director · 1 trade KALA KALA BIO, Inc. 10% owner · 7 trades CTKB Cytek Biosciences, Inc. Director · 21 trades PHAT Phathom Pharmaceuticals, Inc. 10% owner · 4 trades RYTM RHYTHM PHARMACEUTICALS, INC. Former 10% Owner · 8 trades PCVX Vaxcyte, Inc. 10% owner · 4 trades PMVP PMV Pharmaceuticals, Inc. 10% owner · 1 trade DYN Dyne Therapeutics, Inc. 10% owner · 1 trade TGTX TG THERAPEUTICS, INC. 10% owner · 1 trade VSTM Verastem, Inc. 10% owner · 2 trades ARVN ARVINAS, INC. Former 10% Owner · 1 trade ACRS Aclaris Therapeutics, Inc. 10% owner · 19 trades CRIS CURIS INC 10% owner · 1 trade
Company
Date
Role
Action
Shares
Amount
Of holding
SION Sionna Therapeutics, Inc.
17 Sep 2026
Director
Sold at will
3,448,811
$21.84M
50.0%
SEPN Septerna, Inc.
12 Aug 2026
Director
Sold at will
1,493,000
$63.45M
67.3%
ARTV Artiva Biotherapeutics, Inc.
31 Jul 2026
Director
Bought
24,944
$247.69K
0.1%
ARTV Artiva Biotherapeutics, Inc.
29 Jul 2026
Director
Bought
20,824
$208.03K
0.1%
ARTV Artiva Biotherapeutics, Inc.
24 Jul 2026
Director
Bought
41,319
$412.78K
0.2%
ARTV Artiva Biotherapeutics, Inc.
23 Jul 2026
Director
Bought
59,880
$596.40K
0.3%
PBLS Parabilis Medicines, Inc.
22 Jul 2026
Director
Bought
47,250
$1.41M
0.2%
ARTV Artiva Biotherapeutics, Inc.
22 Jul 2026
Director
Bought
84,124
$835.35K
0.5%
PBLS Parabilis Medicines, Inc.
21 Jul 2026
Director
Bought
65,923
$1.93M
0.2%
ARTV Artiva Biotherapeutics, Inc.
21 Jul 2026
Director
Bought
120,582
$1.15M
0.7%
PBLS Parabilis Medicines, Inc.
20 Jul 2026
Director
Bought
131,420
$3.58M
0.5%
ARTV Artiva Biotherapeutics, Inc.
17 Jul 2026
Director
Bought
7,882
$70.54K
0.0%
ARTV Artiva Biotherapeutics, Inc.
16 Jul 2026
Director
Bought
152,472
$1.36M
0.9%
VOR Vor Biopharma Inc.
16 Jul 2026
10% owner
Sold at will
213
$4.21K
0.0%
ARTV Artiva Biotherapeutics, Inc.
13 Jul 2026
Director
Bought
6,552
$58.57K
0.0%
ARTV Artiva Biotherapeutics, Inc.
10 Jul 2026
Director
Bought
15,102
$135.46K
0.1%
ARTV Artiva Biotherapeutics, Inc.
26 Jun 2026
Director
Bought
1,876
$16.85K
0.0%
ARTV Artiva Biotherapeutics, Inc.
25 Jun 2026
Director
Bought
31,000
$275.28K
0.2%
HOWL Werewolf Therapeutics, Inc.
17 Jun 2026
10% owner
Sold at will
416,911
$145.92K
57.9%
COAG Hemab Therapeutics Holdings, Inc.
16 Jun 2026
10% owner
Bought
61,523
$1.54M
1.0%
ARTV Artiva Biotherapeutics, Inc.
16 Jun 2026
Director
Bought
124,893
$1.11M
0.8%
HOWL Werewolf Therapeutics, Inc.
16 Jun 2026
10% owner
Sold at will
149,625
$55.36K
31.1%
COAG Hemab Therapeutics Holdings, Inc.
15 Jun 2026
10% owner
Bought
6,146
$152.97K
0.1%
ARTV Artiva Biotherapeutics, Inc.
15 Jun 2026
Director
Bought
15,414
$138.57K
0.1%
HOWL Werewolf Therapeutics, Inc.
15 Jun 2026
10% owner
Sold at will
128,770
$50.22K
27.4%
ARTV Artiva Biotherapeutics, Inc.
12 Jun 2026
Director
Bought
391,019
$3.35M
2.4%
HOWL Werewolf Therapeutics, Inc.
12 Jun 2026
10% owner
Sold at will
170,441
$68.18K
32.8%
PBLS Parabilis Medicines, Inc.
11 Jun 2026
Director
Bought
21,188,750
$423.78M
416%
ARTV Artiva Biotherapeutics, Inc.
11 Jun 2026
Director
Bought
548,580
$4.34M
3.5%
HOWL Werewolf Therapeutics, Inc.
11 Jun 2026
10% owner
Sold at will
262,503
$99.75K
42.1%
HOWL Werewolf Therapeutics, Inc.
10 Jun 2026
10% owner
Sold at will
45,923
$16.99K
10.8%
ARTV Artiva Biotherapeutics, Inc.
10 Jun 2026
Director
Bought
103
$721.00
0.0%
ARTV Artiva Biotherapeutics, Inc.
9 Jun 2026
Director
Bought
479,039
$3.31M
3.2%
HOWL Werewolf Therapeutics, Inc.
9 Jun 2026
10% owner
Sold at will
369,800
$136.83K
49.2%
COAG Hemab Therapeutics Holdings, Inc.
20 May 2026
10% owner
Bought
996
$24.84K
0.0%
COAG Hemab Therapeutics Holdings, Inc.
19 May 2026
10% owner
Bought
3,802
$94.94K
0.1%
COAG Hemab Therapeutics Holdings, Inc.
12 May 2026
10% owner
Bought
6,387
$159.04K
0.1%
HOWL Werewolf Therapeutics, Inc.
12 May 2026
10% owner
Sold at will
101,151
$64.74K
19.9%
ARTV Artiva Biotherapeutics, Inc.
11 May 2026
Director
Bought
6,510,416
$75.00M
74.9%
COAG Hemab Therapeutics Holdings, Inc.
11 May 2026
10% owner
Bought
39,869
$989.23K
0.6%
HOWL Werewolf Therapeutics, Inc.
11 May 2026
10% owner
Sold at will
87,490
$58.62K
17.5%
HOWL Werewolf Therapeutics, Inc.
8 May 2026
10% owner
Sold at will
376,526
$267.33K
47.3%
COAG Hemab Therapeutics Holdings, Inc.
8 May 2026
10% owner
Bought
1,483
$37.05K
0.0%
COAG Hemab Therapeutics Holdings, Inc.
7 May 2026
10% owner
Bought
9,906
$242.32K
0.2%
COAG Hemab Therapeutics Holdings, Inc.
6 May 2026
Director
Bought
68,018
$1.67M
1.1%
COAG Hemab Therapeutics Holdings, Inc.
5 May 2026
Director
Bought
97,411
$2.40M
1.6%
COAG Hemab Therapeutics Holdings, Inc.
4 May 2026
Director
Bought
2,675,000
$48.15M
77.0%
VOR Vor Biopharma Inc.
22 Apr 2026
Director
Sold at will
165,150
$2.60M
6.4%
VOR Vor Biopharma Inc.
20 Apr 2026
Director
Sold at will
171,963
$2.71M
6.3%
VOR Vor Biopharma Inc.
17 Apr 2026
Director
Sold at will
458,411
$7.46M
14.3%
VOR Vor Biopharma Inc.
15 Apr 2026
Director
Sold at will
53,644
$858.84K
1.6%
VOR Vor Biopharma Inc.
14 Apr 2026
Director
Sold at will
153,735
$2.46M
4.5%
VOR Vor Biopharma Inc.
13 Apr 2026
Director
Sold at will
530,610
$8.57M
13.5%
VOR Vor Biopharma Inc.
10 Apr 2026
Director
Sold at will
828
$13.04K
0.0%
VOR Vor Biopharma Inc.
9 Apr 2026
Director
Sold at will
135,201
$2.24M
3.3%
VOR Vor Biopharma Inc.
8 Apr 2026
Director
Sold at will
484,104
$7.98M
10.6%
VOR Vor Biopharma Inc.
6 Apr 2026
Director
Sold at will
589,257
$9.78M
11.5%
VOR Vor Biopharma Inc.
2 Apr 2026
Director
Sold at will
260,000
$4.74M
4.8%
WVE Wave Life Sciences, Inc.
30 Mar 2026
Director
Bought
971,091
$6.31M
3.7%
MLYS Mineralys Therapeutics, Inc.
30 Mar 2026
Director
Bought
58,300
$1.41M
1.0%
WVE Wave Life Sciences, Inc.
27 Mar 2026
Director
Bought
2,495,623
$16.05M
10.6%
MLYS Mineralys Therapeutics, Inc.
27 Mar 2026
Director
Bought
310,700
$7.35M
5.7%
WVE Wave Life Sciences, Inc.
26 Mar 2026
Director
Bought
5,305,782
$32.27M
29.1%
BCAX Bicara Therapeutics Inc.
26 Feb 2026
Director
Bought
300,000
$4.80M
7.0%
ACET Adicet Bio, Inc.
20 Feb 2026
10% owner
Bought
74,751
$543.44K
6.7%
ACET Adicet Bio, Inc.
19 Feb 2026
10% owner
Bought
74,268
$535.47K
7.2%
ACET Adicet Bio, Inc.
18 Feb 2026
10% owner
Bought
74,577
$525.02K
7.8%
SGP SpyGlass Pharma, Inc.
9 Feb 2026
Director
Bought
3,690,000
$59.04M
162%
CLYM Climb Bio, Inc.
5 Jan 2026
Director
Bought
7,111
$24.89K
0.2%
CLYM Climb Bio, Inc.
12 Dec 2025
Director
Bought
101,462
$290.18K
3.1%
CLYM Climb Bio, Inc.
11 Dec 2025
Director
Bought
213,099
$464.56K
6.9%
FULC Fulcrum Therapeutics, Inc.
8 Dec 2025
10% owner
Sold at will
4,175,139
$58.38M
40.8%
SION Sionna Therapeutics, Inc.
21 Nov 2025
Director
Sold at will
25,183
$994.73K
13.7%
SION Sionna Therapeutics, Inc.
20 Nov 2025
Director
Sold at will
5,133
$205.98K
3.0%
SION Sionna Therapeutics, Inc.
19 Nov 2025
Director
Sold at will
47,442
$1.90M
22.0%
SION Sionna Therapeutics, Inc.
18 Nov 2025
Director
Sold at will
6,922
$273.90K
3.7%
SION Sionna Therapeutics, Inc.
17 Nov 2025
Director
Sold at will
81,987
$3.33M
30.8%
WVE Wave Life Sciences, Inc.
13 Nov 2025
Director
Bought
1,000
$6.69K
0.0%
EVMN Evommune, Inc.
7 Nov 2025
Director
Bought
1,250,000
$20.00M
87.8%
VOR Vor Biopharma Inc.
30 Oct 2025
Director
Sold at will
24,579
$617.42K
3.1%
VOR Vor Biopharma Inc.
29 Oct 2025
Director
Sold at will
251,518
$6.34M
23.8%
VOR Vor Biopharma Inc.
28 Oct 2025
Director
Sold at will
124,311
$3.41M
10.5%
SION Sionna Therapeutics, Inc.
28 Oct 2025
Director
Sold at will
62,610
$2.48M
23.0%
VOR Vor Biopharma Inc.
27 Oct 2025
Director
Sold at will
90,941
$2.56M
7.2%
SION Sionna Therapeutics, Inc.
24 Oct 2025
Director
Sold at will
311,000
$12.28M
58.6%
VOR Vor Biopharma Inc.
24 Oct 2025
Director
Sold at will
53,345
$1.49M
4.0%
VOR Vor Biopharma Inc.
23 Oct 2025
Director
Sold at will
76,880
$2.15M
5.5%
VOR Vor Biopharma Inc.
21 Oct 2025
Director
Sold at will
25,027
$703.51K
1.8%
VOR Vor Biopharma Inc.
20 Oct 2025
Director
Sold at will
92,023
$2.73M
100%
VOR Vor Biopharma Inc.
17 Oct 2025
Director
Sold at will
260,859
$7.67M
94.5%
VOR Vor Biopharma Inc.
16 Oct 2025
Director
Sold at will
151,803
$4.47M
72.4%
VOR Vor Biopharma Inc.
15 Oct 2025
Director
Sold at will
51,363
$1.57M
38.3%
PEPG PepGen Inc.
26 Sep 2025
Director
Bought
9,375,000
$30.00M
102%
MLYS Mineralys Therapeutics, Inc.
4 Sep 2025
Director
Bought
1,176,470
$30.00M
27.5%
TYRA Tyra Biosciences, Inc.
16 Jun 2025
Director
Bought
11,813
$119.67K
0.1%
TYRA Tyra Biosciences, Inc.
13 Jun 2025
Director
Bought
120,167
$1.23M
1.2%
TYRA Tyra Biosciences, Inc.
12 Jun 2025
Director
Bought
31,307
$319.33K
0.3%
TYRA Tyra Biosciences, Inc.
9 Jun 2025
Director
Bought
186,850
$1.90M
1.9%
TYRA Tyra Biosciences, Inc.
5 Jun 2025
Director
Bought
213,334
$2.14M
2.2%
TYRA Tyra Biosciences, Inc.
4 Jun 2025
Director
Bought
997,864
$9.61M
11.5%
HOWL Werewolf Therapeutics, Inc.
14 May 2025
Director
Bought
162,539
$159.29K
2.7%
HOWL Werewolf Therapeutics, Inc.
13 May 2025
Director
Bought
52,974
$51.91K
0.9%
HOWL Werewolf Therapeutics, Inc.
12 May 2025
Director
Bought
320,913
$275.99K
5.6%
MLYS Mineralys Therapeutics, Inc.
13 Mar 2025
Director
Bought
1,296,296
$17.50M
43.4%
JANX Janux Therapeutics, Inc.
7 Mar 2025
Director
Bought
110,206
$3.42M
1.1%
JANX Janux Therapeutics, Inc.
6 Mar 2025
Director
Bought
372,093
$11.45M
3.9%
JANX Janux Therapeutics, Inc.
5 Mar 2025
Director
Bought
341,742
$10.47M
3.7%
SION Sionna Therapeutics, Inc.
10 Feb 2025
Director
Bought
1,125,000
$20.25M
19.4%
TYRA Tyra Biosciences, Inc.
8 Nov 2024
Director
Bought
1,220,681
$19.84M
16.3%
SEPN Septerna, Inc.
28 Oct 2024
Director
Bought
4,170,000
$75.06M
308%
JANX Janux Therapeutics, Inc.
18 Oct 2024
Director
Bought
1,200,000
$53.70M
14.8%
BCAX Bicara Therapeutics Inc.
16 Sep 2024
Director
Bought
1,833,000
$32.99M
74.2%
ANTX AN2 Therapeutics, Inc.
9 Aug 2024
10% owner
Sold at will
3,525,094
$3.81M
92.1%
ARTV Artiva Biotherapeutics, Inc.
22 Jul 2024
Director
Bought
8,333,333
$100.00M
×23
CLYM Climb Bio, Inc.
27 Jun 2024
Director
Bought
13,008,546
$49.95M
124%
JBIO Jade Biosciences, Inc.
17 Jun 2024
Director
Bought
928,110
$1.55M
13.3%
BOLD Boundless Bio, Inc.
2 Apr 2024
10% owner
Bought
312,500
$5.00M
19.9%
NKTX Nkarta, Inc.
27 Mar 2024
Director
Bought
3,000,000
$30.00M
42.5%
SPRY ARS Pharmaceuticals, Inc.
27 Mar 2024
Director
Bought
505,954
$4.95M
5.4%
SPRY ARS Pharmaceuticals, Inc.
26 Mar 2024
Director
Bought
457,745
$4.37M
5.1%
SPRY ARS Pharmaceuticals, Inc.
25 Mar 2024
Director
Bought
437,600
$3.96M
5.1%
LENZ LENZ Therapeutics, Inc.
21 Mar 2024
Director
Bought
933,038
$14.02M
39.1%
LENZ LENZ Therapeutics, Inc.
21 Mar 2024
Director
Bought
64,971
$976.51K
10.3%
PEPG PepGen Inc.
9 Feb 2024
Director
Bought
2,557,593
$27.21M
38.6%
SLDB Solid Biosciences Inc.
11 Jan 2024
Director
Bought
904,160
$5.00M
27.5%
WVE Wave Life Sciences, Inc.
11 Dec 2023
Director
Bought
1,000,000
$5.00M
5.5%
SPRY ARS Pharmaceuticals, Inc.
21 Sep 2023
Director
Bought
2,700,000
$8.18M
46.1%
SPRY ARS Pharmaceuticals, Inc.
29 Aug 2023
Director
Bought
3,750,000
$23.25M
178%
ANTX AN2 Therapeutics, Inc.
18 Aug 2023
10% owner
Bought
1,777,778
$16.00M
52.9%
ABOS Acumen Pharmaceuticals, Inc.
21 Jul 2023
Director
Bought
5,161,290
$40.00M
65.5%
JANX Janux Therapeutics, Inc.
19 Jul 2023
Director
Bought
495,008
$6.17M
6.5%
BDTX Black Diamond Therapeutics, Inc.
5 Jul 2023
Director
Bought
935,850
$4.68M
41.1%
MLYS Mineralys Therapeutics, Inc.
14 Feb 2023
Director
Bought
1,250,000
$20.00M
203%
FULC Fulcrum Therapeutics, Inc.
20 Jan 2023
10% owner
Bought
1,923,076
$25.00M
19.9%
HOWL Werewolf Therapeutics, Inc.
6 Jan 2023
Director
Bought
1,853,000
$4.10M
48.2%
FULC Fulcrum Therapeutics, Inc.
4 Jan 2023
10% owner
Bought
180,703
$1.31M
1.9%
ELVN Enliven Therapeutics, Inc.
3 Jan 2023
10% owner
Bought
629,297
$2.52M
19.4%
FULC Fulcrum Therapeutics, Inc.
27 Dec 2022
10% owner
Bought
4,089
$24.51K
0.0%
FULC Fulcrum Therapeutics, Inc.
19 Dec 2022
10% owner
Bought
98,787
$582.81K
1.1%
FULC Fulcrum Therapeutics, Inc.
16 Dec 2022
10% owner
Bought
1,341,420
$7.27M
16.6%
FULC Fulcrum Therapeutics, Inc.
15 Dec 2022
10% owner
Bought
237,029
$1.30M
3.0%
FULC Fulcrum Therapeutics, Inc.
14 Dec 2022
10% owner
Bought
824,600
$4.50M
11.8%
ELVN Enliven Therapeutics, Inc.
9 Dec 2022
10% owner
Bought
19,299
$75.85K
0.6%
ELVN Enliven Therapeutics, Inc.
8 Dec 2022
10% owner
Bought
10,600
$39.75K
0.3%
ACRV Acrivon Therapeutics, Inc.
17 Nov 2022
Director
Bought
3,389,500
$42.37M
341%
ELVN Enliven Therapeutics, Inc.
24 Oct 2022
10% owner
Bought
26,460
$103.46K
0.8%
ELVN Enliven Therapeutics, Inc.
21 Oct 2022
10% owner
Bought
48,100
$188.55K
1.5%
ELVN Enliven Therapeutics, Inc.
20 Oct 2022
10% owner
Bought
11,342
$44.80K
0.4%
ELVN Enliven Therapeutics, Inc.
19 Oct 2022
10% owner
Bought
125,726
$488.66K
4.2%
ELVN Enliven Therapeutics, Inc.
18 Oct 2022
10% owner
Bought
234,799
$882.84K
8.5%
ELVN Enliven Therapeutics, Inc.
17 Oct 2022
10% owner
Bought
145,672
$489.46K
5.5%
ANTX AN2 Therapeutics, Inc.
4 Aug 2022
10% owner
Bought
100
$799.00
0.0%
ANTX AN2 Therapeutics, Inc.
3 Aug 2022
10% owner
Bought
1,809
$13.53K
0.0%
ANTX AN2 Therapeutics, Inc.
27 Jul 2022
10% owner
Bought
8,281
$65.50K
0.2%
ANTX AN2 Therapeutics, Inc.
26 Jul 2022
10% owner
Bought
14,938
$115.17K
0.4%
ANTX AN2 Therapeutics, Inc.
21 Jun 2022
10% owner
Bought
302
$2.41K
0.0%
WVE Wave Life Sciences, Inc.
16 Jun 2022
Director
Bought
9,480,052
$20.38M
123%
ANTX AN2 Therapeutics, Inc.
14 Jun 2022
10% owner
Bought
61,424
$489.40K
1.7%
ANTX AN2 Therapeutics, Inc.
13 Jun 2022
10% owner
Bought
20,000
$158.00K
0.5%
KALA KALA BIO, Inc.
26 May 2022
10% owner
Sold, plan not stated
1,005,686
$365.67K
12.5%
KALA KALA BIO, Inc.
25 May 2022
10% owner
Sold, plan not stated
1,434,509
$602.49K
15.1%
KALA KALA BIO, Inc.
24 May 2022
10% owner
Sold, plan not stated
144,805
$73.85K
1.5%
KALA KALA BIO, Inc.
23 May 2022
10% owner
Sold, plan not stated
1,250,000
$812.50K
11.5%
PEPG PepGen Inc.
10 May 2022
Director
Bought
3,229,200
$38.75M
95.2%
NKTX Nkarta, Inc.
26 Apr 2022
Director
Bought
2,200,000
$33.00M
39.2%
ANTX AN2 Therapeutics, Inc.
29 Mar 2022
10% owner
Bought
1,666,666
$25.00M
105%
CTKB Cytek Biosciences, Inc.
15 Mar 2022
Director
Bought
241,727
$2.96M
1.8%
CTKB Cytek Biosciences, Inc.
14 Mar 2022
Director
Bought
342,143
$4.22M
2.7%
CTKB Cytek Biosciences, Inc.
11 Mar 2022
Director
Bought
337,492
$4.31M
2.7%
CTKB Cytek Biosciences, Inc.
10 Mar 2022
Director
Bought
256,992
$3.33M
2.1%
CTKB Cytek Biosciences, Inc.
9 Mar 2022
Director
Bought
40,154
$521.75K
0.3%
CTKB Cytek Biosciences, Inc.
8 Mar 2022
Director
Bought
245,701
$3.16M
2.1%
CTKB Cytek Biosciences, Inc.
7 Mar 2022
Director
Bought
337,901
$4.26M
2.9%
CTKB Cytek Biosciences, Inc.
4 Mar 2022
Director
Bought
63,662
$827.23K
0.6%
CTKB Cytek Biosciences, Inc.
2 Mar 2022
Director
Bought
138,255
$1.78M
1.2%
CTKB Cytek Biosciences, Inc.
1 Mar 2022
Director
Bought
294,864
$3.83M
2.7%
CTKB Cytek Biosciences, Inc.
28 Feb 2022
Director
Bought
8,746
$113.43K
0.1%
CTKB Cytek Biosciences, Inc.
25 Feb 2022
Director
Bought
18,991
$246.70K
0.2%
CTKB Cytek Biosciences, Inc.
24 Feb 2022
Director
Bought
186,467
$2.43M
1.7%
CTKB Cytek Biosciences, Inc.
23 Feb 2022
Director
Bought
214,922
$2.88M
2.0%
CTKB Cytek Biosciences, Inc.
22 Feb 2022
Director
Bought
214,922
$2.89M
2.1%
CTKB Cytek Biosciences, Inc.
18 Feb 2022
Director
Bought
166,229
$2.35M
1.6%
CTKB Cytek Biosciences, Inc.
17 Feb 2022
Director
Bought
166,229
$2.46M
1.6%
CTKB Cytek Biosciences, Inc.
16 Feb 2022
Director
Bought
166,200
$2.49M
1.7%
CTKB Cytek Biosciences, Inc.
15 Feb 2022
Director
Bought
166,200
$2.49M
1.7%
CTKB Cytek Biosciences, Inc.
14 Feb 2022
Director
Bought
166,229
$2.45M
1.7%
TYRA Tyra Biosciences, Inc.
17 Sep 2021
Director
Bought
1,250,000
$20.00M
30.9%
CLYM Climb Bio, Inc.
12 Aug 2021
Director
Bought
3,200,000
$40.00M
43.2%
CTKB Cytek Biosciences, Inc.
27 Jul 2021
Director
Bought
2,950,000
$50.15M
59.4%
ABOS Acumen Pharmaceuticals, Inc.
6 Jul 2021
Director
Bought
1,875,000
$30.00M
31.2%
JBIO Jade Biosciences, Inc.
2 Jul 2021
Director
Bought
2,785,714
$39.00M
66.6%
HOWL Werewolf Therapeutics, Inc.
16 Jun 2021
Director
Bought
9,285
$124.14K
0.2%
JANX Janux Therapeutics, Inc.
15 Jun 2021
Director
Bought
2,941,176
$50.00M
62.8%
HOWL Werewolf Therapeutics, Inc.
15 Jun 2021
Director
Bought
7,958
$103.06K
0.2%
HOWL Werewolf Therapeutics, Inc.
14 Jun 2021
Director
Bought
306,055
$3.90M
7.7%
HOWL Werewolf Therapeutics, Inc.
4 May 2021
Director
Bought
1,715,000
$27.44M
94.8%
SLDB Solid Biosciences Inc.
19 Mar 2021
Director
Bought
2,206,685
$12.69M
25.3%
PHAT Phathom Pharmaceuticals, Inc.
11 Mar 2021
10% owner
Sold, plan not stated
710,000
$31.06M
18.6%
VOR Vor Biopharma Inc.
9 Feb 2021
Director
Bought
2,979,566
$53.63M
56.0%
RYTM RHYTHM PHARMACEUTICALS, INC.
3 Dec 2020
Former 10% Owner
Sold, plan not stated
207,604
$6.03M
4.5%
RYTM RHYTHM PHARMACEUTICALS, INC.
2 Dec 2020
Former 10% Owner
Sold, plan not stated
30,939
$1.00M
0.7%
PCVX Vaxcyte, Inc.
8 Oct 2020
10% owner
Sold, plan not stated
167,661
$8.50M
3.2%
PCVX Vaxcyte, Inc.
7 Oct 2020
10% owner
Sold, plan not stated
98,597
$5.02M
1.9%
PCVX Vaxcyte, Inc.
30 Sep 2020
10% owner
Sold, plan not stated
124,656
$6.27M
2.3%
PMVP PMV Pharmaceuticals, Inc.
29 Sep 2020
10% owner
Bought
950,000
$17.10M
125%
PCVX Vaxcyte, Inc.
29 Sep 2020
10% owner
Sold, plan not stated
80,707
$4.20M
1.5%
DYN Dyne Therapeutics, Inc.
21 Sep 2020
10% owner
Bought
660,000
$12.54M
30.8%
TGTX TG THERAPEUTICS, INC.
9 Sep 2020
10% owner
Sold, plan not stated
158,589
$4.09M
1.2%
NKTX Nkarta, Inc.
14 Jul 2020
10% owner
Bought
3,333,333
$60.00M
147%
RYTM RHYTHM PHARMACEUTICALS, INC.
2 Jul 2020
10% owner
Sold, plan not stated
44,153
$972.97K
0.9%
RYTM RHYTHM PHARMACEUTICALS, INC.
1 Jul 2020
10% owner
Sold, plan not stated
25,527
$558.31K
0.5%
RYTM RHYTHM PHARMACEUTICALS, INC.
30 Jun 2020
10% owner
Sold, plan not stated
61,901
$1.37M
1.2%
RYTM RHYTHM PHARMACEUTICALS, INC.
29 Jun 2020
10% owner
Sold, plan not stated
52,049
$1.15M
1.0%
RYTM RHYTHM PHARMACEUTICALS, INC.
26 Jun 2020
10% owner
Sold, plan not stated
86,706
$2.02M
1.6%
VSTM Verastem, Inc.
25 Jun 2020
10% owner
Sold, plan not stated
1,161,300
$2.22M
6.7%
RYTM RHYTHM PHARMACEUTICALS, INC.
25 Jun 2020
10% owner
Sold, plan not stated
11,568
$289.77K
0.2%
VSTM Verastem, Inc.
27 Apr 2020
10% owner
Sold, plan not stated
1,301,300
$3.00M
7.0%
PHAT Phathom Pharmaceuticals, Inc.
1 Apr 2020
10% owner
Bought
117,600
$2.92M
3.2%
PHAT Phathom Pharmaceuticals, Inc.
31 Mar 2020
10% owner
Bought
30,600
$751.26K
0.8%
PHAT Phathom Pharmaceuticals, Inc.
27 Mar 2020
10% owner
Bought
30,000
$738.00K
0.8%
ELVN Enliven Therapeutics, Inc.
16 Mar 2020
10% owner
Bought
625,000
$10.00M
75.4%
KALA KALA BIO, Inc.
13 Mar 2020
Director
Bought
6,337,135
$50.00M
140%
WVE Wave Life Sciences, Inc.
24 Jan 2019
Director
Bought
263,158
$10.00M
3.5%
KALA KALA BIO, Inc.
3 Oct 2018
Director
Bought
2,424,242
$20.00M
115%
ARVN ARVINAS, INC.
1 Oct 2018
Former 10% Owner
Bought
1,000,000
$16.00M
46.8%
WVE Wave Life Sciences, Inc.
14 Nov 2017
Director
Bought
23,398
$561.55K
0.3%
WVE Wave Life Sciences, Inc.
13 Nov 2017
Director
Bought
400,000
$9.32M
5.6%
KALA KALA BIO, Inc.
25 Jul 2017
Director
Bought
533,333
$8.00M
33.8%
ACRS Aclaris Therapeutics, Inc.
16 Sep 2016
10% owner
Sold, plan not stated
173,600
$4.25M
7.6%
ACRS Aclaris Therapeutics, Inc.
15 Sep 2016
10% owner
Sold, plan not stated
351,950
$8.46M
13.4%
ACRS Aclaris Therapeutics, Inc.
23 Feb 2016
10% owner
Bought
28,408
$500.51K
1.1%
ACRS Aclaris Therapeutics, Inc.
22 Feb 2016
10% owner
Bought
11,318
$180.96K
0.4%
ACRS Aclaris Therapeutics, Inc.
20 Jan 2016
10% owner
Bought
1,803
$35.85K
0.1%
ACRS Aclaris Therapeutics, Inc.
19 Jan 2016
10% owner
Bought
4,200
$83.48K
0.2%
ACRS Aclaris Therapeutics, Inc.
15 Jan 2016
10% owner
Bought
1,800
$35.74K
0.1%
ACRS Aclaris Therapeutics, Inc.
13 Jan 2016
10% owner
Bought
5,543
$110.67K
0.2%
ACRS Aclaris Therapeutics, Inc.
12 Jan 2016
10% owner
Bought
5,941
$113.58K
0.2%
ACRS Aclaris Therapeutics, Inc.
11 Jan 2016
10% owner
Bought
4,153
$74.48K
0.2%
WVE Wave Life Sciences, Inc.
16 Nov 2015
Director
Bought
1,875,000
$30.00M
36.0%
ACRS Aclaris Therapeutics, Inc.
29 Oct 2015
10% owner
Bought
95,000
$1.33M
3.8%
ACRS Aclaris Therapeutics, Inc.
28 Oct 2015
10% owner
Bought
149,200
$2.09M
6.4%
ACRS Aclaris Therapeutics, Inc.
22 Oct 2015
10% owner
Bought
5,410
$75.88K
0.2%
ACRS Aclaris Therapeutics, Inc.
21 Oct 2015
10% owner
Bought
3,100
$45.98K
0.1%
ACRS Aclaris Therapeutics, Inc.
20 Oct 2015
10% owner
Bought
7,965
$119.07K
0.3%
ACRS Aclaris Therapeutics, Inc.
19 Oct 2015
10% owner
Bought
23,934
$356.05K
1.0%
ACRS Aclaris Therapeutics, Inc.
14 Oct 2015
10% owner
Bought
42,813
$601.79K
1.9%
ACRS Aclaris Therapeutics, Inc.
8 Oct 2015
10% owner
Bought
21,691
$238.56K
1.0%
ACRS Aclaris Therapeutics, Inc.
7 Oct 2015
10% owner
Bought
2,215,439
$24.05M
opened
CRIS CURIS INC
15 Apr 2008
10% owner
Sold, plan not stated
1,300,000
$1.82M
17.2%
249 decisions on file.